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Abstract
Background: Exposure of red blood cells to oxidants increases production of methemoglobin (MHb) resulting in
impaired oxygen delivery to tissues. There are no reliable estimates of methemoglobinemia in low resource clinical
settings. Our objectives were to: i) evaluate risk factors for methemoglobinemia in Ugandan children hospitalized
with fever (study 1); and ii) investigate MHb responses in critically ill Ugandan children with severe malaria treated
with inhaled nitric oxide (iNO), an oxidant that induces MHb in a dose-dependent manner (study 2).
Methods: Two prospective studies were conducted at Jinja Regional Referral Hospital in Uganda between 2011
and 2013. Study 1, a prospective cohort study of children admitted to hospital with fever (fever cohort, n = 2089
children 2 months to 5 years). Study 2, a randomized double-blind placebo-controlled parallel arm trial of room air
placebo vs. 80 ppm iNO as an adjunctive therapy for children with severe malaria (RCT, n = 180 children 1–10 years
receiving intravenous artesunate and 72 h of study gas). The primary outcomes were: i) masimo pulse co-oximetry
elevated MHb levels at admission (>2 %, fever cohort); ii) four hourly MHb levels in the RCT.
Results: In the fever cohort, 34 % of children admitted with fever had elevated MHb at admission. Children with a
history of vomiting, delayed capillary refill, elevated lactate, severe anemia, malaria, or hemoglobinopathies had
increased odds of methemoglobinemia (p < 0.05 in a multivariate model). MHb levels at admission were higher in
children who died (n = 89) compared to those who survived (n = 1964), p = 0.008. Among children enrolled in the
iNO RCT, MHb levels typically plateaued within 12–24 h of starting study gas. MHb levels were higher in children
receiving iNO compared to placebo, and MHb > 10 % occurred in 5.7 % of children receiving iNO. There were no
differences in rates of study gas discontinuation between trial arms.
Conclusions: Hospitalized children with evidence of impaired oxygen delivery, metabolic acidosis, anemia, or
malaria were at risk of methemoglobinemia. However, we demonstrated high-dose iNO could be safely
administered to critically ill children with severe malaria with appropriate MHb monitoring.
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Background
An estimated 200 million malaria infections occur every
year, resulting in an estimated 1.2 million deaths [1],
the majority of which are attributable to Plasmodium
falciparum infection. Despite the availability of effective
artemisinin-based antimalarial therapies, mortality rates
remain high in severe malaria (8–20 % in children),
suggesting that therapies targeting the parasite alone are
insufficient in individuals with established manifestations
of severe disease. One potential strategy to reduce mortal-
ity rates is to identify adjunctive therapies that target dele-
terious host immune responses (reviewed in [2, 3]). The
endothelium, acting as a ‘biosensor’, is increasingly being
recognized as a critical regulator of vascular integrity in
life-threatening infections characterized by systemic in-
flammation, like sepsis and severe malaria, and therefore
represents a promising target for adjunctive therapy [4].
One strategy to promote endothelial integrity is to
increase bioavailable nitric oxide (NO), a gaseous free
radical produced by the conversion of L-arginine to L-
citrulline through a family of nitric oxide synthase en-
zymes [5]. A number of human studies have reported
associations between reduced bioavailable NO and malaria
disease severity [6–8]. Preclinical data from an experimen-
tal model of cerebral malaria (CM) reported improved
survival, reduced systemic inflammation and endothelial
activation, and retained blood-brain-barrier integrity fol-
lowing administration of iNO [9, 10]. iNO is approved
for human use (5–80 ppm), and is routinely used in
North America and Europe for the treatment of persistent
pulmonary hypertension or infant respiratory distress syn-
drome in term or near-term neonates [11, 12]. Based on
these data, we sought to evaluate whether iNO would im-
prove clinical recovery when administered in adjunct to
standard anti-malarial therapy in a cohort of children with
severe malaria [13, 14].
As iNO is systemically absorbed it combines with
hemoglobin to form nitrosylhemoglobin, which is then
oxidized to form methemoglobin (MHb) [15]. MHb is
formed by oxidation of ferrous iron (Fe++) to ferric iron
(Fe+++) within the heme moiety of hemoglobin (Hb),
resulting in a functional impairment in the ability of Hb
to transport oxygen and carbon dioxide [16]. As red blood
cells (RBCs) are continuously bathed in oxygen, there is
constant oxidation of Hb to MHb, but levels of MHb typ-
ically remain <1 % due to endogenous reduction systems
[17]. Elevated levels of MHb (>10 %) can lead to clinical
signs of hypoxemia ranging from mild headache to re-
spiratory distress, cyanosis and death with increasing
levels of MHb. Although methemoglobinemia typically oc-
curs following ingestion or skin exposure to an oxidizing
agent, it can also occur as a result of genetic, dietary or
other factors [18].
In this study, we prospectively evaluated MHb levels
in Ugandan children hospitalized with fever. Our objec-
tives were three-fold: i) to determine MHb levels at ad-
mission among children hospitalized for febrile illness in
Ugandan children; ii) to explore clinical and demographic
factors associated with elevated MHb; and iii) to evaluate
the safety and tolerability of high-dose inhaled nitric oxide
in children with severe malaria using MHb. We assessed
the first two objectives in a prospective observational
study of 2089 febrile children admitted to hospital in a
resource-constrained hospital in Eastern Uganda. The
impact of iNO on MHb was assessed in a randomized
double-blind placebo-controlled trial evaluating iNO as an
adjunctive therapy for children with severe malaria where
iNO was administered at 80 ppm continuously for up to
72 h. Although iNO is routinely administered in neonates
at doses of 5–20 ppm, there are limited data on the effect
of iNO on MHb levels at higher doses, and no data from
pediatric populations in Africa.
Methods
Study site
Studies took place at the Jinja Regional Referral Hospital
between July 2011 and August 2013 in Jinja, Uganda.
The hospital serves a catchment area of 3 million people
encompassing 12 districts in mid-eastern Uganda. The
children’s unit has 100 beds and an average admission
rate of 650 children per month. Malaria transmission in
the Jinja area is moderate with an estimated entomological
inoculation rate of six infective bites per person per year
[19, 20]. Malaria is the most common admission diagnosis
in the children’s unit.
Study 1 design: prospective in-patient study of children
hospitalized with non-malarial and malarial fever
Children aged 2 months to 5 years were eligible for the
study if they had a documented fever or history of fever
within the previous 48 h and were admitted to hospital
by the attending physician. Children with diarrheal ill-
ness without any other symptoms of systemic infection
were excluded from the study. At admission, information
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was collected on patient demographics, history of illness,
and treatments. Daily follow-up was conducted by study
personnel to determine clinical outcome. Methemoglobin
was assessed using a Masimo SET® Rad-57™ pulse co-
oximeter (Masimo Corporation, Irvine, CA), by experi-
enced pediatric nurses and medical officers according to
standard operating procedures. Malaria infection (lab-con-
firmed malaria) was defined using microscopy (Field’s
stained thick blood smear examined by an experienced
technician at the Jinja Hospital Laboratory using a light
microscope) and/or rapid diagnostic tests (HRP2/pLDH
positive or pLDH positive test, First Response MalariaAg.
pLDH/HRP2 Combo Rapid Diagnostic Test, Premier
Medical Corporation Limited, India) [21].
Study 2 design: randomized double-blind placebo-controlled
clinical trial comparing air versus high-dose iNO as an
adjunctive therapy for severe malaria
Children aged 1 to 10 years with suspected severe
malaria were screened in the emergency department at
Jinja Regional Referral Hospital for inclusion in the
trial. The trial is registered (ClinicalTrials.gov Identifier:
NCT01255215). Children were eligible for the study if
they had a positive malaria rapid diagnostic test in the
presence of features of severe malaria [13]. After obtaining
informed consent, children were randomized to receive
either room air or iNO starting at 80 ppm by non-
rebreather HiOx® face mask (CareFusion, CA) for 72 h
(or until the child recovered and no longer tolerated
the mask). Children were randomized using simple
randomization using a computer generated list created
by the unblinded team leader (ALC). Group assignment
was recorded on a piece of paper and kept in sequentially
sealed opaque envelops in a locked cabinet accessible only
to un-blinded investigators. Following enrollment, malaria
was confirmed using thick and thin Giemsa-stained
peripheral blood smears assessed by light microscopy
at the Makerere University-John’s Hopkins University
(MU-JHU) Core Lab, which is a College of American
Pathologists certified, quality-controlled central research
laboratory in Kampala. All children received parenteral
artesunate for severe malaria as described [22]. Children
were excluded from the study if they had known chronic
illnesses (e.g. renal, cardiac or hepatic diseases, epilepsy,
cerebral palsy, clinical AIDS), hemoglobinopathies, se-
vere malnutrition (<−3SD weight-for-age), severe mal-
arial anemia (Hb <50 g/L) without any other signs of
severe malaria, and baseline methemoglobinemia (>2 %)
that did not resolve following patient stabilization.
Study gas (continuous iNO or room air placebo) was
administered by an un-blinded research team not in-
volved in patient care including: a trial manager to
randomize children and start treatment gas, and a team
of un-blinded study nurses to monitor gas delivery and
potential toxicities. Study gas was temporarily discon-
tinued if one of the following occurred: MHb >10 %; el-
evated inspired NO2 concentration >5 %; persistent
hypoxemia; evolving respiratory distress; unexplained
tachycardia; unexplained hypotension; any study drug
related adverse event that, in the opinion of the investiga-
tor, made it unsafe for the subject to continue. Following
temporary discontinuation of the study gas, there was the
possibility of re-challenge following resolution of the ad-
verse event. Treatment was permanently discontinued if
there was refractory methemoglobinemia (MHb above
10 % despite re-starting iNO at a lower concentration
following temporary discontinuation); hemoptysis; acute
kidney injury; any study drug related adverse event that, in
the opinion of the investigator, made it unsafe for the
subject to continue; any study drug related adverse
event requiring temporary discontinuation that recurred
on re-challenge at the same or lower dose of iNO; or at
the discretion of the subject or guardian; at the discretion
of the investigator.
Baseline MHb levels were assessed at time of patient
screening and were repeated following randomization.
After the study gas was initiated, MHb levels were
assessed on a four-hourly basis. Nurses kept detailed
clinical record of any time off gas to accurately assess
the time children were exposed to iNO.
Statistical analysis
Data were analyzed using IBM SPSS 20, Stata 13 (Col-
lege Station, TX) and GraphPad Prism 6. Demographic,
clinical and laboratory characteristics of participants at
enrolment were described using proportions for binary
variables and mean or median values for continuous var-
iables, as appropriate. Age and sex-standardized z-scores
for height-for-age, weight-for-age and height-for-weight
were calculated using the World Health Organization
Anthro program (version 3.2.2, January 2011).
Baseline MHb levels were analyzed as a percentage or
categorized as methemoglobinemia (>2 % vs. ≤2 %). Risk
factors for methemoglobinemia at admission were evalu-
ated using bivariate and multivariate logistic regression
models. Model selection for the multivariate model was
based on variables selected a priori (age) and all variables
that predicted methemoglobinemia at an alpha level of
≤0.2 in bivariate logistic regression models. Final variable
selection for the multivariate model balanced parsimony
with model fit based on Hosmer-Lemeshow’s goodness of
fit test, minimizing Akaike’s Information Criteria and
Bayesian Information Criteria. Unadjusted and adjusted
odds ratios are presented with 95 % confidence intervals.
Results
Data were analyzed for 2089 children with known out-
comes in the pediatric fever cohort (study 1) and 180
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children in the iNO RCT (study 2). Median age was
1 year [IQR: 0, 2] in the fever cohort and 2 years [1, 3]
in the iNO RCT (Table 1). Clinical characteristics at
enrollment such as temperature, heart rate, oxygen
saturation, capillary refill time and blood pressure
were comparable in both cohorts. In the fever cohort
(study 1), the median Blantyre coma score (BCS) was
5 [IQR: 5,5], 33 % presented with vomiting and 30 %
presented with diarrhea. In the iNO RCT, the median
BCS was 2 [2, 3] with 4 and 21 % presenting with vomiting
and diarrhea, respectively. Sixty-seven percent of children
in the pediatric fever cohort had lab-confirmed malaria
(by thick film blood smear or positive RDT pLDH/HRP2
or pLDH alone) compared to 100 % in the iNO RCT, an
enrollment criteria for the RCT. Twenty percent and 61 %
of fever and iNO RCT cohorts, respectively, had severe
anemia (Table 1). Median MHb levels at admission were
1.5 % [IQR: 0.7, 2.6] in the fever cohort and 1.7 % [1.2, 2.1]
in the iNO RCT cohort (p >0.05). Sixty-two out of 547
(11.3 %) subjects were excluded from the iNO RCT due to
elevated MHb at admission.
Study 1 cohort: risk factors of elevated MHb in a pediatric
fever cohort
Among 2089 children admitted to the hospital with a fever
(Table 2), 34 % had methemoglobinemia (MHb >2 %), 6 %
had MHb levels above 7, and 3 % had MHb levels above
10 %. In bivariate analysis, multiple factors differed be-
tween children with vs. without methemoglobinemia
(Table 2). In a multivariate logistic regression model,
children with methemoglobinemia at presentation were
significantly more likely to have vomiting (adjusted
odds ratio (aOR) 1.36, 95 % CI: 1.09, 1.70), prolonged
capillary refill time (aOR 1.36, 95 % CI: 1.11, 1.66) and
elevated lactate levels (aOR 1.08, 95 % CI: 1.05, 1.11)
after controlling for relevant demographic, clinical and
laboratory results. The odds ratio of methemoglobinemia
was two times higher in children with hemoglobinopathies
(sickle cell anemia or glucose-6-phosphate dehydrogenase
deficiency (G6PD)) (aOR 1.97, 95 % CI: 1.17, 3.32), or in
severe anemia (aOR 1.99, 95 % CI: 1.51, 2.61). Children
with lab-confirmed malaria (aOR 1.34, 95 % CI: 1.07, 1.69)
also had an elevated risk of methemoglobinemia. Of
children with lab-confirmed malaria, 54.6 % met WHO
criteria for severe malaria, including: prostration, deep
breathing, jaundice, hyperlactatemia, hypoglycemia, se-
vere anemia, altered consciousness or hemoglobinuria.
MHb levels were higher in children with severe malaria
(n = 754; median 1.9 %, IQR, 0.8–4.1) compared to uncom-
plicated malaria (n = 627; median 1.4 %, IQR: 0.7–2.0),
p <0.0001 by Mann-Whitney U test.
Admission MHb levels were higher in non-survivors
(n = 89; median 1.7 %, IQR: 0.8–4.6) compared to survi-
vors (n = 1964; median 1.5 %, IQR: 0.7–2.5), p = 0.008
(Mann-Whitney U Test). Analysis of missing data showed
that MHb values were more likely to be missing in non-
survivors compared to survivors at 10.1 and 1.3 % respect-
ively (reflecting the difficulty in getting pulse co-oximetry
measurements in critically ill children with poor perfusion).
Study 2 cohort: MHb levels in children receiving iNO as
an adjunctive therapy for severe malaria
Overview of trial
Among children enrolled in the iNO RCT, 92 were ran-
domized to receive placebo (room air) and 88 to receive
iNO between July 2011 and June 2013. The mean time
on gas was comparable between groups (mean (SD): pla-
cebo, 63.6 (19.9) hours; iNO, 61.9 (21.7) hours, p = 0.582).
Gas was withdrawn for 31 children (12 children in the pla-
cebo arm and 19 in the iNO arm, p = 0.13). 10 children
had gas temporarily discontinued for the following
reasons: methemoglobin >10 %, n = 5; unexplained tachy-
cardia, n = 1; investigator discretion, n = 4 (stridor, n = 2;
Table 1 Characteristics of Study Cohorts
Fever Cohort
(n = 2089)
iNO Trial Cohort
(n = 180)
Age, yearsa 1 [0, 2] 2 [1, 3]
Male, % (#) 55 % (1134) 57 % (102)
Temperature, °C 37.9 (1.2) 37.9 (1.2)
Heart rate, bpm 159.2 (25.2) 160.7 (25.0)
Systolic BP 105.0 (15.9) 110.5 (20.2)
Diastolic BP 57.4 (13.4) 58.7 (13.6)
Respiratory rate 44 [36, 56] 48 [38, 62]
Vomiting 33 % (686) 4 % (8)
Diarrhea 30 % (614) 21 % (38)
Blantyre coma score 5 [5, 5] 2 [2, 3]
SpO2 98 [96, 100] 99 [98, 100]
Lactate (mmol/L)b 2.7 [1.9, 4.9] 3.6 [2.1, 6.4]
Lactate >5 mmol/Lb 24 % (485) 24 % (43)
Capillary refill time
<2 s 85 % (1724) 82 % (148)
2–3 s 10 % (194) 12 % (22)
>3 s 5 % (106) 6 % (10)
Lab-confirmed malariac 67 % (1240) 100 %
Severe anemiad 20 % (428) 61 % (109)
Pretreatment with antibiotic 33 % (682) 43 % (74)
Pretreatment with antimalarial 46.2 % (956) 59 % (105)
aMean (SD) for normally distributed variables. Median [IQR] for non-normally
distributed variables. Number (%) for categorical variables
bLactate was assessed using LactateScout in the fever cohort and i-STAT in the
iNO trial as previously described [52]
cPositive by microscopy or RDT (HRP2/pLDH or pLDH)
dSevere anemia defined as hemoglobin less than 5 g/dL (hospital laboratory)
or pallor by clinical assessment in the fever cohort and Hb <5 g/dL (reference
laboratory) in the iNO trial cohort
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resuscitation, n = 1; transfer to another hospital for trans-
fusion, n = 1). 21 children had gas permanently discontin-
ued for the following reasons: acute kidney injury, n = 10;
guardian withdrew consent, n = 2; technical/power issues,
n = 2; mask required for oxygen delivery, n = 1; recovery/
refusal to tolerate the mask, n = 6. There were no differ-
ences between rates of temporary (placebo, n = 3 vs. iNO,
n = 7; p = 0.21) or permanent discontinuation (placebo,
n = 10 vs. iNO, n = 12; p = 0.57) of study gas between
trial arms. However, MHb >10 % requiring temporary
withdrawal of study gas only occurred in children receiv-
ing iNO (n = 5, 5.7 %), p = 0.026. Apart from elevated
MHb, there were no other study drug-related adverse
events listed in the product monograph (hypotension, atel-
ectasis, hematuria, hyperglycemia, sepsis, infection, stridor,
cellulitis) [23].
MHb response to iNO administration
As this is the largest trial reported to date to administer
nitric oxide at 80 ppm (the highest FDA approved dose),
Table 2 Factors associated with methemoglobinemia in a pediatric fever cohort
MHb ≤2 %
N = 1364 (66 %)
MHb >2 %
N = 689 (34 %)
Bivariate OR
(95 % CI)
P-value Multivariate OR
(95 % CI)
P-value
Demographic characteristics
Age, months 17 [9, 26] 18 [9, 30] 1.00 (1.00, 1.01) 0.268 1.00 (1.00, 1.01) 0.370
Age <6 months 98 (7.2) 53 (7.7) 1.08 (0.76, 1.52) 0.677
Male (%) 734 (54.4) 382 (56.1) 1.07 (0.89, 1.29) 0.461
Clinical findings at admission
Fever (≥38o C) 402 (39.1) 276 (27.6) 0.59 (0.49, 0.72) <0.001 0.74 (0.60, 0.92) 0.005
Underweight, <-2 WAZ 303 (22.6) 150 (22.3) 0.97 (0.77, 1.21) 0.775
Systolic BP 105.5 (15.3) 104.2 (7.0) 0.99 (0.99, 1.00) 0.094
Diastolic BP 58.4 (13.3) 55.6 (13.4) 0.98 (0.98, 0.99) <0.001 0.99 (0.98, 1.00) 0.130
Age-specific elevated respiratory rate, per min 693 (52.7) 398 (59.8) 1.34 (1.11, 1.62) 0.002
Deep breathing 282 (20.7) 213 (31.0) 1.72 (1.40, 2.12) <0.001
Vomiting 399 (29.3) 272 (39.6) 1.58 (1.30, 1.91) <0.001 1.36 (1.09, 1.70) 0.007
Diarrhea 424 (31.2) 176 (25.6) 0.82 (0.64, 0.) 0.008 0.82 (0.64, 1.04) 0.107
Blantyre coma score
0
1
2
3
4
5
21 (1.6)
13 (1.0)
22 (1.6)
45 (3.4)
63 (4.7)
1173 (87.7)
26 (3.9)
9 (1.3)
25 (3.7)
41 (6.1)
48 (8.6)
514 (76.4)
0.78 (0.71, 0.85) <0.001
Capillary refill time
< 2 seconds 1180 (89.5) 515 (77.0)
2- <3 sec 90 (6.8) 102 (15.2)
≥ 3 sec 49 (3.7) 49 (3.7) 1.81 (1.52, 2.16) <0.001 1.36 (1.11, 1.66) 0.003
Pretreatment with antibiotics 428 (31.6) 240 (35.5) 1.19 (0.98, 1.45) 0.079
Pretreatment with sulfadoxine pyremethamine 16 (1.2) 14 (2.1) 1.76 (0.85, 3.63) 0.125
Subcostal retractions 236 (17.3) 172 (25.0) 1.59 (1.27, 1.98) <0.001
Laboratory test results at admission
Lactate, mmol/L 2.5 [1.8, 4.0] 3.4 [2.2, 8.5] 1.14 (1.11, 1.16) <0.001 1.08 (1.05, 1.11) <0.001
Glucose, mmol/L 7.1 (2.3) 7.9 (3.3) 1.11 (1.07, 1.15) <0.001
Oxygen saturation (Sp02) 98 [96, 100] 98 [95, 99] 0.97 (0.95, 0.99) 0.015
Severe anemia, Hb < 5 g/dL or pallor 182 (13.3) 233 (33.8) 3.32 (2.66, 4.14) <0.001 1.99 (1.51, 2.61) <0.001
Suspected hemoglobinopathy 41 (3.0) 41 (6.0) 2.04 (1.31, 3.18) 0.002 1.97 (1.17, 3.32) 0.011
Lab-confirmed malaria1 883 (64.8) 498 (72.5) 1.43 (1.17, 1.74) 0.001 1.34 (1.07, 1.69) 0.011
Mean (SD) for normally distributed variables. Median [IQR] for non-normally distributed variables. Number (%) for categorical variables
1Positive by microscopy or RDT (HRP2/pLDH or pLDH)
Factors significantly associated with methemoglobinemia in bivariate or multivariate analysis in bold
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and methemoglobinemia is a known complication of
iNO, we investigated the impact of 80 ppm iNO on
MHb levels. This represents a secondary analysis of the
study. The primary efficacy data are presented elsewhere
[24]. MHb levels were assessed at scheduled times on a
four hourly basis following study gas initiation. The
mean time between initiation of study gas and the first
gas check was 2.2 h, during which time there was a 2.3
fold-mean increase in MHb percent among children re-
ceiving iNO (mean MHbBaseline = 1.8 to 4.1 %) but no
change in children receiving placebo (mean MHbBaseline
= 1.7 to 1.8 %). Although there was considerable variabil-
ity in MHb responses over time, MHb levels typically
peaked and plateaued within 12–24 h of receiving nitric
oxide (Fig. 1a). To illustrate the variability in MHb levels
over time, representative plots of MHb levels over
hospitalization were generated for a randomly selected
subset (10 %) of study participants (n = 17; n = 7 placebo
arm, n = 10 nitric oxide arm) (Fig. 1b). Representative
graphs are shown for children who received study gas
without interruption (A–C), children with temporary in-
terruptions to gas flow (D–F), children who had study gas
permanently discontinued because of acute kidney in-
jury (G–I), and deaths (J–L) (Fig. 2).
MHb levels in fatal malaria
In the iNO RCT, we did not observe a significant difference
between MHb levels assessed following randomization and
mortality (MHb levels ≤2 % at screening was an eligibility
requirement), p = 0.071 by Mann-Whitney U test. The
majority of study deaths occurred in the first 48 h of
hospitalization (n = 14 of 16 total deaths; [n = 8 in the
placebo group, n = 6 in the iNO group]) with over half
of study deaths (n = 8, 57.1 %) occurring before a second
MHb measurement was taken. The mean time from study
enrollment to death was 13 h. Because longitudinal data
on MHb levels in non-survivors was limited, we were un-
able to explore differences in temporal trends in MHb
levels between survivors and non-survivors.
Of children with multiple MHb measurements taken
prior to death, there was one case of rising MHb prior
to death. A 1 year old presented to the emergency de-
partment with a 3-day history of fever having received
pre-referral treatment with chloramphenicol and intra-
venous quinine. The child was prostrate and comatose
(Blantyre coma score = 2) with convulsions, prolonged
capillary refill time (>3 s), jaundice, hypoglycemia, and
severe anemia. At presentation, the patient had cough
and age-related tachypnea (respiratory rate, 56/min) but
no other signs of respiratory distress (nasal flaring, deep
breathing, subcostal retractions). A diagnosis of severe
malaria was made and the patient was treated with intra-
venous artesunate, dextrose, diazepam and phenobarbit-
one. Following enrollment in the clinical trial, the child
was transferred to the study ward and study gas (room
air) was initiated. On arrival to the study ward, the lac-
tate level was 2.3 μmol/L and the MHb level was 0 %.
Over the course of several hours, the child deteriorated
clinically and developed respiratory distress with nasal
flaring and intercostal and subcostal retractions and a
progressive decline in Sp02 % to a nadir of 87 %. Supple-
mental oxygen was administered, but MHb levels con-
tinued to rise reaching 9.3 % before death (Fig. 2j). The
cause of death was cardiopulmonary arrest.
Among children who died receiving iNO, only one
had multiple MHb measurements taken prior to death
(Fig. 2l).
Discussion
In this study, we examined levels of MHb in two cohorts
of children presenting to a regional pediatric referral
hospital in Eastern Uganda. Although these studies rep-
resent distinct patient populations (there was no patient
overlap between studies), the subjects were enrolled over
the same 2 year period from the same catchment area.
Overall, the children enrolled in the fever cohort were
younger (according to the study design) and included all
Fig. 1 MHb levels in children with severe malaria randomized to room air or nitric oxide as an adjunctive therapy to intravenous artesunate.
a Box and whisker plots showing the median (IQR) and 95 % CI for the trial arms at scheduled four hourly MHb checks. b Representative MHb
plots for a random subset (10 %) of study participants (n = 7 placebo arm, n = 10 nitric oxide arm)
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Fig. 2 Representative graphs of methemoglobin kinetics and nitric oxide concentrations administered to children with severe malaria over
hospitalization. a, b, c Representative plots from children receiving study gas with no interruptions to study gas. d, e, f Graphs showing MHb
kinetics in children with a temporary interruption to study gas administration. g, h, i Graphs from children who had study gas permanently
discontinued because they met criteria for acute kidney injury. j, k, l, Graphs from non-survivors
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causes of fever, whereas all children in the iNO RCT had
a diagnosis of severe malaria.
Among children enrolled in the fever cohort, there
were no differences in MHb levels based on demo-
graphic characteristics (age, sex, or nutritional status).
Infants less than 6 months represent a vulnerable group
for methemoglobinemia for a number of reasons, includ-
ing: a higher pH in the stomach that permits the growth
of nitrate-reducing organisms (e.g. Escherichia coli,
Salmonella spp.); immature NADH-methemoglobin re-
ductase systems with reduced capacity to cope with oxida-
tive stress (levels at birth are only 50–60 % of adult levels)
[18, 25, 26]; the presence of fetal hemoglobin which is
more readily oxidized to MHb than adult Hb [18]; and a
higher consumption of water per unit body weight, which
renders them susceptible to methemoglobinemia if ex-
posed to nitrates through drinking water [27]. Despite
these known risk factors in young children, we did not
observe an age-dependent effect on MHb levels in our
population of children hospitalized with fever.
Given the high rate of methemoglobinemia in our
cohort (34 % of children in the fever cohort had MHb
>2 %), Ugandan children may be at higher risk for
methemoglobinemia than populations from high-resource
settings as their environmental exposures may result in a
higher set-point for MHb. A common cause of MHb in
children is ingestion or contact with direct or indirect oxi-
dizing agents (e.g. benzocaine, chloroquine, primaquine,
sulfonamides, nitrites/nitrates, dapsone). As a result, we
explored whether there was an association between known
drug exposures (e.g. pretreatments with antibiotics
and/or anti-malarials) and MHb levels. There was a
non-significant increase in the odds of elevated
methemoglobinemia in children that received pretreat-
ment with any antibiotic (Table 2, p = 0.079). Due to
the variability in antibiotic prescription and limitations
in parental recall, we were limited in our ability to ex-
plore relationships between specific classes of drugs
and MHb levels. Furthermore, we were unable to assess
environmental exposure to other oxidizing agents in in
this population (e.g., nitrates in water, or smoke inhalation
through indoor biomass fuel use). However, a study evalu-
ating nitrate levels in spring water from central Uganda re-
ported 60 % (52/80) of water samples had nitrate levels
exceeding the WHO maximum permissible levels [28]. In
addition, widespread reliance on biomass fuel use (e.g.,
wood) in cooking stoves or open fires contributes to high
levels of indoor air pollution [29]. It is estimated that 78 %
of the Ugandan population resides in rural areas where
86 % use wood for cooking [29, 30]. Based on these find-
ings, it is likely that environmental exposure to oxidants in
our population exceeds WHO recommended levels.
We explored the association between clinical signs and
symptoms at hospital presentation and MHb levels, and
observed two general trends. First, children with impaired
perfusion and acidosis (vomiting, delayed capillary refill,
and elevated lactate) had significantly higher odds of
methemoglobinemia after controlling for a set of potential
confounders. These findings are consistent with previous
studies in infants where methemoglobinemia was reported
in the context of metabolic acidosis secondary to diarrhea
and dehydration [31, 32]. In our cohort, we observed
increased odds of methemoglobinemia associated with
vomiting, but not diarrhea. Children with fever and
diarrhea alone were excluded from the study. The
prevalence of P. falciparum parasitemia in this cohort
was high at 67 %. Therefore, the acidosis observed in
this study may be attributable to malaria rather than
dehydration and diarrhea, as metabolic acidosis is a
common complication of malaria [33–35]. These data
suggest that in conditions of increased inflammation,
oxidative stress and acidosis, impaired reduction or re-
conversion of MHb to Hb may contribute to the ele-
vated MHb levels observed in our cohort [18, 36, 37].
Methemoglobinemia was also seen in circumstances
where red blood cells (RBCs) are affected: severe anemia,
children with suspected or documented hemoglobinopa-
thies (i.e. sickle cell disease or G6PD deficiency), and
malaria. RBCs are particularly susceptible to oxidative
damage as they carry oxygen in high concentrations and
are continuously exposed to oxygen free radicals. As
RBCs lack a nucleus, they are dependent on endogenous
reduction systems that can degrade with repeated expos-
ure to oxidants or RBC senescence [38]. Recent estimates
of G6PD polymorphisms in Uganda show 20 % of the
population carry the G6PD A-mutation [39], which are
consistent with the range of estimates 15–32 % described
elsewhere in Africa [40–42]. With increased oxidative
stress on RBCs in G6PD deficiency, sickle cell disease, and
other RBC polymorphisms, the capacity of endogenous re-
duction systems may be overwhelmed leading to increased
MHb. In this population, rates of malaria were high with
roughly two thirds of children admitted to hospital with
fever having parasitologic evidence of malaria infection.
Because quantitative estimates of malaria burden (either
parasitemia or plasma HRP2 antigen levels) were not
available in this cohort, it is difficult to estimate the
fraction of fevers in children hospitalized attributable
to malaria. Regardless, malaria was independently asso-
ciated with increased odds of methemoglobinemia (OR
(95 % CI), 1.34 (1.07, 1.69), p = 0.011), consistent with
previous reports of methemoglobinemia in malaria
[43–46]. Malaria is associated with increased oxidative
stress from malaria-heme products and immune cell de-
rived reactive oxygen species, both of which could pro-
mote oxidation of Hb to MHb [47, 48]. Finally, as children
with severe anemia possess compromised oxygen carrying
capacity, increased levels of MHb in the context of severe
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anemia may exacerbate reduced oxygen delivery resulting
in metabolic acidosis and functional impairments in MHb
reduction. Although elevated MHb was more common in
non-survivors compared to survivors, it is likely that ele-
vated MHb is a consequence of oxidative stress and acid-
osis in severe disease rather than mediating severe disease.
However, in children with potentially symptomatic levels of
MHb (e.g. the 3 % of children with MHb >10 % at admis-
sion in the fever cohort), MHb could exacerbate underlying
disease processes and treatment may be warranted.
In the context of the clinical trial, 11 % of children assessed
for eligibility were excluded for methemoglobinemia,
which is considerably less than the fever cohort (34 %).
The lower prevalence of methemoglobinemia in the
iNO RCT may be due to a number of factors, including
exclusion of children with known chronic illness (i.e.,
hemoglobinopathy). Furthermore, children otherwise
eligible for the clinical trial were only excluded for
methemoglobinemia if their MHb levels remained ≥2 %
following stabilization (which included administration
of fluids, transfusion in cases of severe anemia, and
dextrose to treat/prevent hypoglycemia). As catabolism
of sugars through glycolysis is a major source of substrate
for the NADH-cytochrome-b5 reductase system, glucose
levels must be in adequate supply for endogenous MHb
reducing systems to respond [18]. Therefore, these
stabilization measures may have contributed to a
reduction in MHb levels in children allowing them to
meet the eligibility criteria for the trial.
We were unable to evaluate the dose-dependent effect
of iNO on MHb levels as all children randomized to re-
ceive iNO were started at 80 ppm. However, this is the
largest trial to date to administer iNO at the maximum
approved dose and we were able to evaluate the variability
in MHb responses within subjects and the frequency of
methemoglobinemia prompting study gas discontinuation.
Despite the high doses of iNO administered, study gas was
temporarily discontinued only five times for MHb >10 %
(all children in the iNO group). We were able to re-start
study gas for all children that had a MHb measurement
that exceeded 10 % once the MHb returned to <7 % with-
out having the MHb exceed 10 % again. It was not neces-
sary to wean children off iNO, in contrast to studies
administering iNO to neonates with hypoxic respiratory
failure, as we did not observe any rebound effects (e.g.
worsening oxygenation) following discontinuation of study
gas [23, 49]. Overall, four hourly MHb checks were suf-
ficient for monitoring iNO administration, with more
frequent checks implemented in children when MHb
levels approached 7 % so appropriate measures could be
taken if levels exceeded 7 or 10 % (e.g. titrate or temporarily
discontinue study gas). As seen in Fig. 3b, MHb levels fluc-
tuated considerably within subjects over hospitalization in
both trial arms. It is not clear whether these fluctuations
Fig. 3 Flow chart of study enrolment for the randomized controlled trial
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were due to natural variations/regulatory responses in the
endogenous reduction systems or were related to MHb
measurement using the pulse co-oximeter. However, per-
formance of non-invasive pulse co-oximetry has been previ-
ously compared to whole blood co-oximetry in children with
sickle cell disease and showed acceptable clinical accuracy
(bias of −0.22 % for MHb) [50]. The variations in MHb levels
over hospitalization highlight the importance of frequent
MHb monitoring during administration of nitric oxide.
When looking at illustrative graphs of MHb kinetics in
children with and without study gas interruptions, the
variability in responses is apparent (Fig. 1). We specif-
ically included a panel of children who had gas per-
manently discontinued for acute kidney injury, as
administration of iNO has been associated with a sta-
tistically elevated risk of developing renal dysfunction
in critically ill adults [51]; however, the same associ-
ation has not been observed in pediatric populations.
In a recent retrospective analysis of acute kidney in-
jury in this cohort, we found iNO was associated with
an increased risk of acute kidney injury compared to
placebo with a relative risk of 1.36 (95 % CI, 1.03-
1.80), p=0.026. We did not observe differences in
MHb levels in children who had gas discontinued for
acute kidney injury compared to other children. Apart
from the one child in the placebo arm of the trial who
had increasing MHb levels prior to death, we did not ob-
serve elevated MHb among trial participants who died.
However, the majority of participants died early in illness
and there were limited kinetic data available. All children
except one (Fig. 2l) died in the iNO arm died before re-
peated MHb measurements were taken.
After a decade of use in clinical practice, iNO has a well-
established safety profile. In this study, we administered
iNO in a low-resource setting in a non-intensive care set-
ting with limited laboratory support. Using a commercially
available handheld pulse co-oximeter, we determined the
range of MHb levels for children admitted to hospital with
fever in this population. Although MHb levels >2 % were
observed in 34 % of children admitted with fever,
methemoglobinemia was grounds for study exclusion
in the iNO RCT for only 11 % of children following
stabilization and repeat MHb assessment. In addition, we
administered iNO at the highest approved dose in 87 pa-
tients with severe malaria and had to temporarily discon-
tinue study gas for only a fraction of children (5.7 %) with
MHb >10 %. Overall, the rates of study gas withdrawal
were not different between the placebo and trial arm.
Our study strengths include two integrated studies
encompassing a single catchment area: a large prospective
observational study to describe MHb levels in children
hospitalized with fever, and an intervention where a potent
Hb oxidant was administered and MHb levels assessed.
The clinical trial was randomized and double blinded
using separate teams to monitor clinical care and study
gas administration to ensure clinical decisions to withdraw
gas were not affected by intervention. The study gas team
used pre-set standard operating procedures to guide
decisions regarding titration or withdrawal of study gas.
Although we were limited in our ability to report dose-
dependent effects of iNO on MHb levels, our study is
the largest to administer iNO at the maximum approved
dose and serves as an important addition to existing
literature.
Conclusions
Methemoglobinemia was a common complication among
febrile Ugandan children admitted to hospital, and was as-
sociated with vomiting, metabolic acidosis, anemia, red
blood cell polymorphisms, and malaria. Among children
with severe malaria challenged with high-dose iNO, there
was an increase in MHb levels, but rates of gas withdrawal
for elevated MHb levels were low. These data suggest that
iNO therapy, if clinically warranted, can be administered
in low-resource settings provided appropriate monitoring
is implemented.
Key messages
 Methemoglobinemia (MHB >2 %) was a common
feature among febrile Ugandan children admitted to
hospital
 Elevated MHb was independently associated with
vomiting, prolonged capillary refill time, and
metabolic acidosis
 Children with anemia, red blood cell polymorphisms
(e.g. sickle cell disease, G6PD deficiency), or malaria
had elevated MHb at admission
 Administration of high-dose (80 ppm) inhaled nitric
oxide in children with severe malaria resulted in
increased MHb levels that plateaued 12–24 h after
study gas initiation
 Inhaled nitric oxide was safe and well-tolerated in
critically ill Ugandan children with severe malaria
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